Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Immuneering adds biotech veteran Thomas Schall to board

EditorEmilio Ghigini
Published 12/03/2024, 11:48 pm
© Reuters.
IMRX
-

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), an oncology company in the clinical stage, announced today the addition of Dr. Thomas J. Schall, a seasoned biotech leader, to its Board of Directors. Dr. Schall brings a wealth of experience from his tenure as Chairman, CEO, and Founder of ChemoCentryx (NASDAQ:CCXI), which was acquired by Amgen (NASDAQ:AMGN) in 2022.

Ben Zeskind, CEO of Immuneering, expressed the company's honor in welcoming Dr. Schall to the board. Zeskind highlighted Dr. Schall's 25-year track record in drug discovery and development as a valuable asset for Immuneering's mission to create broad-spectrum cancer therapies.

Dr. Schall expressed his enthusiasm for joining Immuneering during a pivotal phase as the company progresses its pipeline of universal-RAS/RAF cancer medicines. He looks forward to contributing to the strategic direction of the company and supporting the development of new cancer treatments.

With a history of significant contributions to the field of chemokine system function and activities, Dr. Schall's expertise is expected to be highly influential for Immuneering. His background includes roles at DNAX Research Institute and Genentech, Inc., and he holds a Ph.D. in cancer biology from Stanford University.

Immuneering is focused on developing universal-RAS/RAF medicines for a wide range of cancer patients. Its lead product candidate, IMM-1-104, is an oral inhibitor currently in a Phase 1/2a study targeting advanced solid tumors with RAS mutations. Another candidate, IMM-6-415, is preparing for a Phase 1/2a study for tumors with RAS or RAF mutations. The company's approach aims to inhibit the MAPK pathway cyclically, impacting cancer cells while sparing healthy cells.

This announcement is based on a press release statement from Immuneering Corporation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.